TMCnet News
Two Innovus Pharma Products Officially Listed in OTC Section of the RED BOOK™Innovus Pharmaceuticals, Inc. ("Innovus Pharma" or the "Company") (OTCQB Venture Market: INNV), an emerging over-the-counter ("OTC") consumer goods and specialty pharmaceutical company engaged in the commercialization, licensing and development of safe and effective non-prescription medicine and consumer care products to improve men's and women's health and vitality and respiratory diseases, today announced that two of its flagship products, FlutiCare® for nasal allergy relief and UriVarx® for bladder health, have been approved for listing in the RED BOOK™ pharmacy pricing database, an essential resource for healthcare professionals. RED BOOK™ provides the latest pricing and product information on prescription and over-the-counter drug products within the industry. The listing enables healthcare professionals to quickly answer drug-related questions with information for 200,000+ prescription and over-the-counter drugs, nutraceuticals and bulk chemicals. The RED BOOK™ serves as a resource for drug utilization reviews, market analysis and research, prescription pricing, and order entry. This critical resource establishes and validates reimbursement, forecasting, drug-pricing research, generic substitution, therapeutic interchange, competitive analysis, purchasing, forumulary development and management, as well as claims adjudication, processing and validation. The RED BOOK™ is the oldest source of drug pricing information in the U.S. It also provides details for each product listed therein, including Wholesale Acquisition Cost ("WAC (News - Alert)"), Direct Price ("DP"), Suggested Retail Price ("SRP"), and Federal Upper Limit ("FUL"). "We are very pleased with the inclusion of two of our main products, FlutiCare® and UriVarx® within the RED BOOK™," said Innovus CEO Dr. Bassam Damaj. "This is an important milestone, which validates the national recognition of our products and on their availability to all pharmacies in the United States." About FlutiCare® FlutiCare® is the Company's nationally branded over-the-counter ("OTC") fluticasone propionate nasal spray, USP 50 mcg per spray, which is indicated to treat individuals with allergic rhinitis, or more commonly referred to as "allergies". Allergic rhinitis is one of the most common ailments in the western world and is continuing to grow as there are approximately 50 million sufferers in the U.S. alone according to GlobalData. FlutiCare® is the first and only nationally branded OTC product under approved ANDA No. 207957 in the U.S. market. FlutiCare®, which is equivalent to Flonase® by GlaxoSmithKline and ClariSpray® by Bayer, is the third national brand being marketed and sold in the U.S. Innovus Pharma launched the 120-spray version through its various marketing and sales channels in November 2017. For more information on the product visit www.fluticare.com. The trademark Flonase® is a registered trademark owned by GlaxoSmithKline and the trademark ClariSpray® is a registered trademark owned by Bayer®. About UriVaRx® UriVarx® has undergone two double blind and comparative trials in both male and female OAB and UI patients. The clinical results include:
The NAFC (National Association for Continence) estimated that over 33 million Americans suffer from Overactive Bladder with a market size over $2.1 billion (Source: IMS Health). The product is available through www.urivarx.com and through the Beyond Human® print and online platform reaching between 20-30 million Americans on a monthly basis. About Innovus Pharmaceuticals, Inc. Headquartered in San Diego, Innovus Pharma is an emerging OTC consumer goods and specialty pharmaceutical company engaged in the commercialization, licensing and development of safe and effective non-prescription medicine and consumer care products to improve men's and women's health and vitality and respiratory diseases. Innovus Pharma delivers innovative and uniquely presented and packaged health solutions through its (a) OTC medicines and consumer and health products, which we market directly, (b) commercial partners to primary care physicians, urologists, gynecologists and therapists, and (c) directly to consumers through our on-line channels, retailers and wholesalers. The Company is dedicated to being a leader in developing and marketing new OTC and branded Abbreviated New Drug Application ("ANDA") products. The Company is actively pursuing opportunities where existing prescription drugs have recently, or are expected to, change from prescription (or Rx) to OTC. For more information, go to www.innovuspharma.com; www.zestra.com; www.ejectdelay.com; www.myvesele.com; www.urivarx.com; www.sensumplus.com; www.myandroferti.com; www.beyondhumantestosterone.com; www.getbeyondhuman.com; www.trybeyondhuman.com; www.recalmax.com; www.prostagorx.com; www.fluticare.com; www.allervarx.com; and www.apeaz.com.
Innovus Pharma's Forward-Looking Safe Harbor: Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, projected revenues from the sales of its FlutiCare® and UriVarx® products, estimated market for these and other of its products, and statements about achieving its other development, growth, commercialization, financial and staffing objectives. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's most recent filing on Form S-1, annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC (News - Alert). Copies of these reports are available from the SEC's website or without charge from the Company.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171214005401/en/ |
